IndraLab

Statements

FADH2 inhibits JAK1. 3 / 3
| 3
reach
"Ruxolitinib is an FDA approved drug for the treatment of myelofibrosis and specifically inhibits Jak1 and Jak2."
27738655
reach
"In one of them, we treated the PBMCs and CMCs after three days for additional three days with the JAK inhibitor (JAKi) baricitinib, a small molecule used to treat patients with moderate to severe RA by inhibiting JAK1 and JAK2 as approved by the Food and Drug Administration (FDA)."
39716911
reach
"Ruxolitinib is an FDA approved targeting JAK1 and JAK2 inhibitor."
| PMC